Literature DB >> 28603652

Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration.

Alessandro Tuzi1, Elena Bolzacchini1, Matteo B Suter1, Alice Giaquinto1, Antonio Passaro2, Stefania Gobba1, Ilaria Vallini1, Graziella Pinotti1.   

Abstract

As the leading cause of death worldwide, lung cancer has proven itself incurable in the advanced stages. For early stages, endobronchial ultrasounds transbronchial needle aspiration (EBUS-TBNA) is now considered the standard to assess mediastinal lymph node, to define the multimodality therapeutic approach. In recent years, EBUS-TBNA has extended its use also in the metastatic and locally recurrent disease. New molecules, with specific mutations that give resistance to current target therapies, have made re-biopsy at disease progression an important assessment, with therapeutic and clinical implication. Here we present the oncologist's point of view on EBUS-TBNA in the staging process, at recurrence and progression.

Entities:  

Keywords:  Endobronchial ultrasounds (EBUS); T790M; lung cancer; re-biopsy; review

Year:  2017        PMID: 28603652      PMCID: PMC5459872          DOI: 10.21037/jtd.2017.04.09

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

Review 1.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors:  Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

2.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

Authors:  William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.

Authors:  Jun Araki; Isamu Okamoto; Ryuichiro Suto; Yasuko Ichikawa; Ji-ichiro Sasaki
Journal:  Lung Cancer       Date:  2004-12-09       Impact factor: 5.705

4.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

5.  Personalized medicine and inhibition of EGFR signaling in lung cancer.

Authors:  Adi F Gazdar
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.

Authors:  Takeshi Yoshida; Guolin Zhang; Matthew A Smith; Alex S Lopez; Yun Bai; Jiannong Li; Bin Fang; John Koomen; Bhupendra Rawal; Kate J Fisher; Y Ann Chen; Michiko Kitano; Yume Morita; Haruka Yamaguchi; Kiyoko Shibata; Takafumi Okabe; Isamu Okamoto; Kazuhiko Nakagawa; Eric B Haura
Journal:  Clin Cancer Res       Date:  2014-06-11       Impact factor: 12.531

8.  Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

Authors:  Ryotaro Morinaga; Isamu Okamoto; Kazuyuki Furuta; Yukiko Kawano; Masaru Sekijima; Kensaku Dote; Takao Satou; Kazuto Nishio; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  Lung Cancer       Date:  2007-06-29       Impact factor: 5.705

9.  Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.

Authors:  Neal Navani; James M Brown; Matthew Nankivell; Ian Woolhouse; Richard N Harrison; Vandana Jeebun; Mohammed Munavvar; Benjamin J Ng; Doris M Rassl; Mary Falzon; Gabrijela Kocjan; Robert C Rintoul; Andrew G Nicholson; Sam M Janes
Journal:  Am J Respir Crit Care Med       Date:  2012-04-13       Impact factor: 21.405

10.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316

View more
  3 in total

Review 1.  Radiation-Induced Lung Injury: Assessment and Management.

Authors:  Alexander N Hanania; Walker Mainwaring; Yohannes T Ghebre; Nicola A Hanania; Michelle Ludwig
Journal:  Chest       Date:  2019-04-15       Impact factor: 9.410

Review 2.  Convex probe endobronchial ultrasound: historical, contemporary, and cutting-edge applications.

Authors:  Sameer K Avasarala; Carlos Aravena; Francisco A Almeida
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

Review 3.  Towards Machine Learning-Aided Lung Cancer Clinical Routines: Approaches and Open Challenges.

Authors:  Francisco Silva; Tania Pereira; Inês Neves; Joana Morgado; Cláudia Freitas; Mafalda Malafaia; Joana Sousa; João Fonseca; Eduardo Negrão; Beatriz Flor de Lima; Miguel Correia da Silva; António J Madureira; Isabel Ramos; José Luis Costa; Venceslau Hespanhol; António Cunha; Hélder P Oliveira
Journal:  J Pers Med       Date:  2022-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.